ALA-Based MRI Contrast Agent for Tumor Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nuclear magnetic resonance (NMR) diagnostic agents, such as gadolinium complexes, have toxicity issues and lack site-specificity, leading to inadequate contrast and higher doses required for effective imaging.
Innovation Solution
A nuclear magnetic resonance diagnostic agent comprising 5-aminolevulinic acid (ALA) or its derivatives, which are metabolically activated to Protoporphyrin IX (PpIX), selectively accumulating in specific cells or tissues, enhancing T2-weighted image contrast in MRI without significant side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If gadolinium complexes (e.g., Gd-DTPA) are used as contrast agents, then T1-weighted image contrast is improved, but toxicity and side effects increase
Solution Approach 1:
The patent uses 5-aminolevulinic acid (ALA) as a biodegradable contrast agent that is metabolized by the body through natural pathways. ALA is converted to protoporphyrin IX (PpIX) which accumulates selectively in tumor tissues, providing contrast without long-term toxicity. The agent is excreted naturally, eliminating the persistent toxicity issues associated with gadolinium complexes.
Solution Approach 2:
The patent introduces ALA as an intermediary substance that undergoes metabolic conversion to PpIX, which then accumulates in target tissues. This intermediary approach allows the contrast agent to be activated selectively in tumor tissues through enzymatic conversion, reducing systemic toxicity while maintaining effective contrast enhancement.
2Measurement precision
If gadolinium complexes are administered to achieve adequate contrast, then T1-weighted image contrast is improved, but site-specificity is reduced
Solution Approach 1:
The patent exploits the differential expression of enzymes involved in heme synthesis between normal and tumor tissues. ALA is converted to PpIX by δ-aminolevulinic acid dehydratase and protoporphyrinogen oxidase, enzymes that are overexpressed in tumor tissues. This results in selective accumulation of PpIX in tumors, providing site-specific contrast enhancement without affecting normal tissues.
Solution Approach 2:
The patent utilizes changes in enzymatic activity parameters between healthy and diseased tissues. The contrast agent's effectiveness depends on the altered metabolic parameters in tumor tissues, specifically the increased activity of heme synthesis enzymes, which convert ALA to PpIX at higher rates in tumors than in normal tissues.
3Measurement precision
If larger doses of gadolinium complexes are administered to overcome lack of site-specificity, then image contrast is improved, but toxicity increases
Solution Approach 1:
The patent employs ALA, a naturally occurring amino acid that is metabolized through normal cellular pathways. The body processes ALA through existing enzymatic routes, converting it to PpIX which is then excreted. This eliminates the need for high doses and reduces toxicity, as the agent follows natural metabolic pathways rather than requiring high concentrations to overcome distribution issues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ALA-based diagnostic agent reduces toxicity and side effects, providing site-specific detection and diagnosis of conditions like tumors with improved T2-weighted image contrast, allowing for smaller doses and better differentiation between normal and tumor tissues.
Implementation Method 1
which are metabolically activated to Protoporphyrin IX (PpIX), selectively accumulating in specific cells or tissues
Implementation Method 2
nuclear magnetic resonance (NMR) phenomenon to computed tomography
Data Source
AI summary
[Problem]To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc.[Solution]When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.